Ibandronic acid

Also known as: Ibandronate sodium

Active ingredient description

Ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone. Their selective action on bone tissue is based on the high affinity of bisphosphonates for bone mineral. Bisphosphonates act by inhibiting osteoclast activity, although the precise mechanism is still not clear. In vivo, ibandronic acid prevents experimentally-induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Ibandronic acid
M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates
Discover more medicines within M05BA06

Medicines

Ibandronic acid is the active ingredient of these drugs:

Drug
Countries

Spain

Brazil

Germany

Lithuania

Australia Austria France Germany Hong Kong

Ireland Lithuania Poland

United States

Hong Kong

Germany

Austria Brazil Cyprus France Germany

Finland

Austria Cyprus Ireland Lithuania Poland

Brazil

Brazil

Poland

Austria Poland

Poland

Lithuania Poland

Brazil

Lithuania Poland

Brazil

Brazil

Austria

United Kingdom

Brazil

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

UMD7G2653W - IBANDRONIC ACID

CAS registry number

114084-78-5 - ibandronic acid

SNOMED-CT

420936009 - Ibandronic acid (substance)